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3IntroductionProstate cancer (PC) is the commonest adult male cancer in the developed world, and the second leading cause of cancer related death in men (1).  The majority of patients are likely to die with, rather than from PC, making it important to identify key pathways that confer poor prognosis, thus minimising overtreatment.
Huggins et al in 1941 demonstrated that PC epithelial growth and survival was dependent upon androgens (2).  Androgen deprivation therapy (or ADT) is often the first line treatment in patients with advanced disease.  This is achieved via drug treatments designed to block androgen activity, either by direct suppression of the Luteinising Hormone Releasing Hormone (LHRH) or Androgen Receptor (AR) axis, thus, mimicking surgical castration.  With time, PC develops resistance to these treatments and the disease progresses to CRPC (castrate resistant PC) form, which is uniformly fatal (3).  Thus, a need exists to identify other signalling pathways in PC development and progression, and design specific treatments that exploit the dependencies and vulnerabilities of CRPC. 





























































4generation of energy via their breakdown by β-oxidation to generate ATP.  The energy demands within cancer cells are much higher than that for non-cancerous cells, at least in part to support uncensored growth and proliferation.  However, the use of FAs to synthesise lipids is of equal importance.  Membrane synthesis, which is a pre-requisite of growth and cell division, is linked to G1 phase of cell cycle (5).  In G1 phase, cell cycle arrest results from suppressed expression of key lipid metabolism genes such as Fatty Acid Synthase (FASN) and Acetyl-CoA Carboxylase (ACC) (6).  Besides membrane synthesis, lipogenesis is necessary for other functions (7).  For instance, de novo synthesis of mono-unsaturated and saturated lipids plays key roles in signal transduction, intracellular trafficking, cell polarisation and migration (8-10).  Each of these processes are often hijacked and deregulated in cancer cells to promote their survival.  As such it is not unreasonable to think that disruption or blocking of the lipid metabolism pathways would be detrimental to tumour cell growth, proliferation and ultimately survival, thus representing potential therapeutic targets. 





























































5through increased β-oxidation and this is not the case in non-tumorigenic cell lines (14), making lipid metabolism an attractive as well as specific avenue for treatment. 
Key Regulators of Lipid Metabolism in PCSterol Regulatory Element-Binding Protein 1 (SREBP1)SREBP1 is a master regulator in FA metabolism.  It controls the transcription of ATP Citrate Lyase (ACYL), ACC, Stearoyl-CoA Desaturase 1 (SCD1) and FASN.  Un-regulated SREBP activation has been linked to obesity, fatty liver disease, insulin resistance, autoimmune diseases, as well as cancer development (15).  It is frequently overexpressed in many cancers and is highly associated with increased tumorgenicity and invasion. 





























































6availability, and control a transcriptional program required for adaptation to hypoxia, which is frequently found in solid tumours such as those of the prostate. 
In addition to response to oxygen and androgens levels, SREBP is also activated by the AKT/PI3K pathway (20, 21).  AKT signalling in a PTEN null environment (a situation common in PC with PTEN loss being a driver mutation in the disease) increases SREBP expression which in turn up-regulates expression of the Low-density Lipoprotein (LDL) receptor, thus increasing the uptake of particles, containing cholesteryl esters (CE).  Depletion of this CE storage led to an impairment in PC aggressiveness, has been observed to attenuate cell growth, both in vitro and in vivo through limitation of the uptake of essential fatty acids (11).





























































7effectors (24).  Interestingly, FXR may also further impact on PC via up-regulation of PTEN (25). Regardless, as a master regulator of lipid metabolism it has been shown that by attenuating its function tumour growth and proliferation are diminished and thus it remains as an attractive drug target.
Peroxisome proliferator-activated receptor gamma (PPARG)PPARG is a transcription factor belonging to the nuclear hormone receptor superfamily.  It is known to have roles in adipocyte differentiation, lipid metabolism, peripheral glucose utilisation and inflammatory response.  It has two isoforms PPARG1 and PPARG2.  PPARG1 is expressed in most tissues whilst PPARG2 is present in adipocytes.  Previous studies have demonstrated its role as a tumour suppressor in a variety of cancers, showing that upon treatment with PPARG agonists that proliferation of tumour cells is reduced (26-30). It was also thought to be the case in PC (31), however our work (32) and that of others (33) has challenged this view. 





























































8therapeutically to stratify patients, identifying those with more aggressive disease who would benefit from a PPARG/FASN derived treatment program.  Furthermore, our work as well as that of others suggests that PPARG does not affect the initiation of the primary tumour (34), at least in the mouse models examined, but has a role more specific to the development of aggressive metastatic disease (32).  In a separate study, a link was also established between PPARG and PC progression, identifying Fatty acid binding protein 5 (FABP5) as a potential agonist for PPARG, with increasing FABP5 and PPARG levels correlating with disease severity (35).  This is in line with earlier work where FABP5 was found to be positively associated with an invasive more aggressive phenotype, which could be abrogated by addition of PPARG inhibitor GW9662, leading the authors to surmise that the metastatic effects they observed through FABP5 over-expression resulted from an FABP5 delivery of fatty acid ligand to nuclear membrane bound PPARG resulting in its activation (36).





























































9showing that AR normally functions to supress PPARG expression within AR positive PC cells (37).  These conflicting observations may simply be because of context and cell line differences, but highlight the need for further investigation into the intersecting regulatory pathways of PPARG and AR, as any potential therapy designed around these axes may lead to a worsening of the disease rather alleviating it.  Indeed, it may be that a two-pronged approach is required, targeting both AR and PPARG simultaneously.
As PPARG has been a therapeutic target in disease areas other than cancer, there are already agents available in the clinic known to target PPARG.  Thiazolidinediones (TZDs) or ‘glitazones’ are agonists of PPARG used in the treatment of type 2 diabetes, through improvements of insulin sensitivity (38).  However, the concentration at which the TZDs are used to treat diabetes are far higher than the concentration required for full PPARG activation and thus the mechanism may in fact be due to a PPARG independent effect (39, 40).  Given the link between diabetes and obesity, and the emerging evidence of the role of obesity and PC (to be discussed later) it is worth re-considering the potential risks of using a drug known to activate PPARG in (these obese and diabetic) men. PPARG represents an exciting new target for cancer therapy, but further investigation is needed to identify the subgroup of patients who would benefit from this targeted treatment.






























































lipids, and are an essential substrate for energy metabolism.  There are two sources of FAs for animal metabolism, namely exogenous (dietary) FAs and endogenous (FASN synthesised) FAs.  FASN synthesises long-chain FAs from acetyl-CoA and malonyl-CoA, producing the 16C FA, palmitate (42).  In healthy individuals, FASN has minimal effect since there is adequate levels of FA available from dietary fat.  Thus, most normal cells will preferentially utilise circulating FA for the synthesis of new structural lipids.  In normal conditions, FASN converts excess carbohydrate into FAs, which are then esterified to triacylglycerols that can be stored (and if needed provide energy via β-oxidation). FASN has been shown to be one of the downstream effectors of the PTEN/PI3K/AKT pathway in the PC cell line LNCaP (43).   Similarly, Migita et al demonstrated that forced overexpression of FASN increased cell proliferation both in vitro and in vivo, dependent on the presence of AR in the PC cells (44).  Knock down of FASN in the same cells triggered apoptosis, suggesting that FASN can act as an oncogene in the presence of AR, and that FASN exerts its oncogenic influence by inhibiting apoptosis.






























































disease progresses, FASN levels correlate with Gleason Scores (tumour differentiation) and PSA levels (48).Upon epithelial to mesenchymal transition (EMT), a process crucial for metastasis, FASN levels appear to rise along with increases in lipid droplet and triacylglycerides (TAG) formation in DU145 PC cells (49).  It remains unclear what role FASN plays in EMT or what the TAGs contained inside the lipid droplets are doing, but it is possible that the accumulation of stored TAGs may contribute to EMT through provision of fuel source with the generation of ATP as well as biomass for membrane synthesis (5).  Inhibition of FASN has been observed to suppress both proliferation and key EMT phenotypes including cell adhesion, migration and invasion (50).  FASN knockdown is observed to reduce the synthesis of phospholipids and triglycerides but not cholesterol (6).  






























































The specific oncogenic nature of FASN in PC seems to mark it out as an ideal candidate for drug development (41).  Its increased levels and function correlating with the most aggressive forms of the disease give promise that such a treatment would potentially be useful at all stages, from chemoprevention up to even the most severe cases.  






























































Despite this it has also been observed that loss of SCD1 function can induce increased ER- and oxidative stress, bought about by accumulation of saturated fatty acids in membrane phospholipids, which induces an unfolded protein response (UPR) (58).  Indeed, it has been shown that PC cells have increased levels of membrane lipid saturation which may protect from free radicals and chemotherapeutics (59).  Intriguingly, out with its direct role in lipid metabolism, proteolytic cleavage of SCD1 protein generates a small peptide that has been shown to can exert a positive effect on the transcriptional activity of AR (60). 
The role of SCD1 in PC therefore seems twofold.  Firstly, to function in its capacity as a desaturase to increase the levels of mono-unsaturated lipids in the cancer cell.  This can meet the increased need for these lipids in rapidly dividing and growing cells.  Secondly, upon proteolytic cleavage of SCD1, a small peptide fragment can enhance AR mediated signalling, thus further promoting PC growth and proliferation.  If a therapy can be designed around this peptide it may be represent an opportunity to attenuate the effects of AR on PC.






























































shown to inhibit the growth of a variety of solid tumours, including PC (6, 61-64).  Both ACC and ACLY expression has been linked to androgens (13).  Reduction in ACLY levels by RNAi and the inhibitor SB-204990 has been observed to cause a dramatic reduction in growth of human PC3 orthografts.  This is due to their higher rate of glycolysis, and correspondingly high rate of glucose-dependent lipid synthesis, making them sensitive to ACLY inhibition (61).  A recent study has demonstrated that it is possible to target the ACLY-AMPK-AR axes to sensitise CRPC cells to AR antagonism (65).  A combined pharmacological approach with an AR antagonist and ACLY inhibition in CRPC cells promotes energetic stress and AMPK activation, resulting in further suppression of AR levels and target gene expression, inhibition of proliferation, and apoptosis.






























































The fat deposit closest to the prostate is the peri-prostatic adipose tissue (PPAT), which is found surrounding the prostate.  PPAT volume, measured both on Magnetic Resonance Imaging (MRI) and Ultrasound (US), has been established as a potential biomarker for PC aggressiveness (69, 70).  Periprostatic fat volume was found to be highest in patients at highest risk of developing Castrate Resistant Prostate Cancer (CRPC).  This highlights a potential role of PPAT in predicting the effectiveness of ADT treatment. 






























































higher Gleason Sum Score, higher pathological tumour (T) stage, lymph node invasion and an increased risk of biochemical recurrence (73).  
A variety of pro-inflammatory cytokines and chemokines are found to increase relative to levels of obesity; one such chemokine IL-6 has been shown to be associated with PC (74, 75) with increasing levels correlating with advanced aggressive castrate resistant metastatic disease (76, 77).  IL-6 is produced by the adipose tissue surrounding the prostate, such as the PPAT, and is involved in regulation of proliferative responses and cell death (78).  Following migration of tumour cells along this chemokine (IL-6) gradient and upon contact with the PPAT, it appears that PPAT volume is reduced, which may be due to re-modelling of the PPAT by the invading tumour (73).  However, given that tumour cells have been observed to induce lipolysis in neighbouring adipocytes and thus parasitise their lipid stores to fuel tumour growth and proliferation (79, 80), it is also possible that this loss of PPAT upon contact with tumour is a result of the tumour utilising the fuel stored there to grow and divide.






























































then feed into the glycolytic pathway of the PC cells (81).  Highlighting the impact of tumour micro-environment, bone marrow adipocytes can alter the gene expression profile of PC cells to enhance utilisation of the glycolytic pathway with concurrent increase in lactate production, indicating a shift to a glycolytic metabolic profile, which is consistent with the Warburg Phenotype (81).  
Fat metabolism targeted treatments for prostate cancerWith the evidence linking PC to lipid metabolism growing, a number of treatment strategies targeting various stages of the pathway have been investigated.






























































inhibition, halting proliferation and inducing cell cycle arrest, as well as preventing the development of androgen resistance in PC cells (84). 
Another molecule, Fatostatin, a synthetic diarylthiazole derivative, is known to block adipogeneis through inhibition of SREBP (85).  It has been observed to bind to SCAP, the escort protein of SREBP, blocking the ER-Golgi translocation of SREBP, and thus preventing its activation (85).  Whilst this work has not been performed in PC, it represents another potential mechanism for blocking SREBP activation (86). 






























































counterintuitive.  Recent work now appears to suggest that PPARG activation may be tumourigenic in PC (32, 33), and compounding this with the fact that those suffering type II diabetes are often overweight/obese, then an activation of PPARG by TZD could accelerate tumourigenesis.  






























































FASN is now accepted as a bona fide oncogene.  Inhibition of FASN has been found to cause selective apoptosis of cancer cell in multiple cancer types (100), however the mechanism behind this remains unclear.  It is possible that loss of FASN affects membrane function, DNA replication or inhibition of anti-apoptotic proteins and/or the accumulation of Malonyl-CoA (101).  The selective apoptotic effects caused by loss of FASN activity on cancer cells make it an attractive target for therapy.  Cerulenin, a naturally derived inhibitor of FASN, is produced by a fungus Cephalosporum caerulens.  Cerulenin binds the B-ketoacyl synthase domain of FASN to suppress its function.  It is highly potent but is also unstable with toxic side effects.  The synthetic analogue C75 of cerulenin was developed with a better side effect profile and greater stability (102).  However, the major side effect of both C75 (and cerlenin) is dramatic and rapid weight loss seemingly resulting from stimulation of carnitine palmitoyltransferase-1 (CPT1), which activates mitochondrial fatty acid oxidation, is the limiting factor in developing these agents as cancer therapies (102, 103). 






























































animal models (105).  Similar to treatments with C75 and cerlenin, EGCG treatment also resulted excessive and speedy weight loss, possibly through activation of CPT1 (103).   The use of CPT1 inhibitors such as etomoxir result in reduced PC growth in vitro and in vivo, so combination therapy with FASN inhibitors may allow inhibition of tumour growth whilst mitigating the unwanted side effects of weight loss. (106). 
Orlistat, an anti-obesity drug, has also been found to inhibit the thioesterase domain of FASN; thus halting PC cell proliferation, inducing apoptosis and reducing tumour cell growth in nude mice (107). In its current formulation, Orlistat is limited as an anti-cancer therapy.  It has a poor solubility and bioavailability, and when given orally is only functional in the areas it directly comes into contact with, inhibiting pancreatic lipases in the gut (107) . 
TVB-2640 is the first-in-class, small molecule reversible inhibitor of FASN that demonstrates Phase I clinical efficacy in KRAS mutant NSCLC, ovarian and breast cancer (108, 109).  In this trial, prolonged stable disease was seen with monotherapy.  In addition, when given in combination with paclitaxel, there is evidence of prolonged stable disease in both NSCLC and breast cancer patients, with a confirmed partial response in an patient with peritoneal serous carcinoma (108).






























































enzymes.  Furthermore, the evidence surrounding the risk of developing more advanced and aggressive PC with increased obesity and gross fat volume surrounding the prostate suggests the importance of lipid pathways not only on primary tumour growth but also on the development of advanced and metastatic disease.








































































































































































































































































































































































































































































































































































































































































































































































Table 1: Key lipid regulating genesGene FunctionSREBP1 Transcription factor, binding sterol regulatory element-1 (SRE1) sites. Activity is governed by AR. It governs lipid homeostasis and metabolism as well as sterol biosynthesis.PPARG Transcription factor of the nuclear hormone receptor family, binding PPAR response elements (PPRE).  It governs the activity of genes involved in lipid metabolism and adipocyte differentiation.FASN Enzyme responsible for the generation of long chain saturated fatty acids from acetyl-CoA and malonyl-CoA. SCD1 Enzyme downstream of FASN responsible for the rate limiting step of converting of saturated fatty acids to unsaturated fatty acids, by insertion of a double bond at the Δ9 position.ACLY Enzyme upstream of FASN responsible for the conversion of citrate to acetyl-CoA. 
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